Management of chronic obstructive pulmonary disease: the Swiss Guidelines

: The new Swiss Chronic Obstructive Pulmonary Disease (COPD) Guidelines are based on a previous version, which was published 10 years ago. The Swiss Respiratory Society felt the need to update the previous document due to new knowledge and novel therapeutic developments about this prevalent and important disease. The recommendations and statements are based on the available literature, on other national guidelines and, in particular, on the GOLD (Global Initiative for Chronic Obstructive Lung Disease) report. Our aim is to advise pulmonary physicians, general practitioners and other health care workers on the early detection and diagnosis, prevention, best symptomatic control, and avoidance of COPD as well as its complications and deterioration. Our current guidelines are on Abstract The new Swiss Chronic Obstructive Pulmonary Disease (COPD) Guidelines are based on a previous version, which was published 10 years ago. The Swiss Respiratory Society felt the need to update the previous document due to new knowledge and novel therapeutic developments about this prevalent and important disease. The recommendations and statements are based on the available literature, on other national guidelines and, in particular, on the GOLD (Glob-al Initiative for Chronic Obstructive Lung Disease) report. Our aim is to advise pulmonary physicians, general practitioners and other health care workers on the early detection and diagnosis, prevention, best symptomatic control, and avoidance of COPD as well as its complications and deterioration.

[1]  A. Buist Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[2]  F. Ram,et al.  Short-acting beta2-agonists for stable chronic obstructive pulmonary disease , 2002 .

[3]  E. Russi,et al.  Improved quality of life after lung volume reduction surgery , 2002, European Respiratory Journal.

[4]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[5]  M. Elliott,et al.  Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome , 2001, Thorax.

[6]  A. Nissinen,et al.  Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study , 2001, Thorax.

[7]  F. Platt,et al.  Let Me See If I Have This Right : Words That Help Build Empathy , 2001, Annals of Internal Medicine.

[8]  C. Brambilla,et al.  Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study , 2001, The Lancet.

[9]  D. Mahler,et al.  Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. , 2001, The European respiratory journal.

[10]  A. Cuvelier,et al.  Noninvasive ventilation and obstructive lung diseases. , 2001, The European respiratory journal.

[11]  N. Zamel,et al.  Lung function 5 yr after lung volume reduction surgery for emphysema. , 2001, American journal of respiratory and critical care medicine.

[12]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[13]  N. Ambrosino,et al.  Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study. , 2001, Chest.

[14]  J. Finnerty,et al.  The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. , 2001, Chest.

[15]  P. Poole,et al.  Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review , 2001, BMJ : British Medical Journal.

[16]  P. Anderson,et al.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.

[17]  M. De Salvo,et al.  In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. , 2001, Chest.

[18]  V. Snow,et al.  Evidence Base for Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease , 2001, Annals of Internal Medicine.

[19]  D. Mccrory,et al.  Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Summary and Appraisal of Published Evidence , 2001, Annals of Internal Medicine.

[20]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[21]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[22]  D. Mccrory,et al.  Management of acute exacerbations of COPD: a summary and appraisal of published evidence. , 2001, Chest.

[23]  M. Saetta,et al.  Pathogenesis and Pathology of COPD , 2001, Respiration.

[24]  N. Konietzko,et al.  Longitudinal Follow-up of Patients With α1-Protease Inhibitor Deficiency Before and During Therapy With IV α1-Protease Inhibitor , 2001 .

[25]  M. Decramer,et al.  The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee. , 2001, The European respiratory journal.

[26]  D. Brooks,et al.  Nutritional intervention in COPD: a systematic overview. , 2001, Chest.

[27]  N. Konietzko,et al.  Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. , 2001, Chest.

[28]  R. Zuwallack,et al.  Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[29]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[30]  H. Schäfers,et al.  Lung volume reduction surgery versus conservative treatment in severe emphysema. , 2000, The European respiratory journal.

[31]  Robert West,et al.  Smoking cessation guidelines for health professionals: an update , 2000, Thorax.

[32]  J. Lieberman Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. , 2000, Chest.

[33]  T. Mineo,et al.  Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. Pulmonary Emphysema Research Group. , 2000, The Annals of thoracic surgery.

[34]  J. Steurer,et al.  The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. , 2000, The European respiratory journal.

[35]  D. Hansell,et al.  Effect of lung-volume-reduction surgery in patients with severe emphysema. , 2000, The New England journal of medicine.

[36]  E. Wouters,et al.  Characterization of Nonresponse to High Caloric Oral Nutritional Therapy in Depleted Patients With Chronic Obstructive Pulmonary Disease , 2000 .

[37]  M. Niederman,et al.  The role of bacteria in exacerbations of COPD. A constructive view. , 2000, Chest.

[38]  M. Elliott,et al.  One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration , 2000, Thorax.

[39]  T L Petty,et al.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. , 2000, Archives of internal medicine.

[40]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[41]  W. Hop,et al.  Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. , 2000, The European respiratory journal.

[42]  A. Buist,et al.  Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. , 2000, Chest.

[43]  M. Littner,et al.  Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[44]  J. V. van Noord,et al.  A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .

[45]  P. O'Malley,et al.  Should Health-Care Systems Pay for Replacement Therapy in Patients With α1-Antitrypsin Deficiency? , 2000 .

[46]  N. Hill Noninvasive ventilation has been shown to be ineffective in stable COPD. , 2000, American journal of respiratory and critical care medicine.

[47]  A. Rossi Noninvasive ventilation has not been shown to be ineffective in stable COPD. , 2000, American journal of respiratory and critical care medicine.

[48]  D. Brooks,et al.  Nutritional support for individuals with COPD: a meta-analysis. , 2000, Chest.

[49]  Barnes Pj Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000 .

[50]  D. Mahler How should health-related quality of life be assessed in patients with COPD? , 2000, Chest.

[51]  S. Hurd,et al.  The impact of COPD on lung health worldwide: epidemiology and incidence. , 2000, Chest.

[52]  N. Payne,et al.  Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial , 2000, The Lancet.

[53]  P. O'Malley,et al.  Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. , 2000, Chest.

[54]  F. Ram,et al.  Short-acting beta 2 agonists for stable COPD. , 2000, The Cochrane database of systematic reviews.

[55]  P. Barnes Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[56]  M. Schluchter,et al.  Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. , 2000, American journal of respiratory and critical care medicine.

[57]  B. Smith,et al.  Long-acting beta2-agonists for chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.

[58]  A. Cripps,et al.  Haemophilus influenzae oral vaccination against acute bronchitis. , 2000, The Cochrane database of systematic reviews.

[59]  T. Lasserson,et al.  Lung volume reduction surgery for diffuse emphysema. , 2000, The Cochrane database of systematic reviews.

[60]  M. Schluchter,et al.  Feasibility of a Clinical Trial of Augmentation Therapy for α1-Antitrypsin Deficiency , 2000 .

[61]  G. Criner,et al.  Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[62]  J. Vestbo,et al.  Prognostic value of nutritional status in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[63]  E. Russi,et al.  Two years' outcome of lung volume reduction surgery in different morphologic emphysema types. , 1999, The Annals of thoracic surgery.

[64]  H A Vrooman,et al.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.

[65]  J. Vestbo,et al.  Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. , 1999, Respiratory medicine.

[66]  A. Adelman Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. , 1999, The Journal of family practice.

[67]  L. Davies,et al.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.

[68]  E. Russi,et al.  Functional and morphological heterogeneity of emphysema and its implication for selection of patients for lung volume reduction surgery. , 1999, The European respiratory journal.

[69]  L. Davies,et al.  Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease. , 1999, QJM : monthly journal of the Association of Physicians.

[70]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[71]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[72]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[73]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[74]  C. Westermann,et al.  Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[75]  U Ackermann-Liebrich,et al.  Long-term ambient air pollution and respiratory symptoms in adults (SAPALDIA study). The SAPALDIA Team. , 1999, American journal of respiratory and critical care medicine.

[76]  Y. Lacasse,et al.  Overviews of respiratory rehabilitation in chronic obstructive pulmonary disease. , 1999, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[77]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[78]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[79]  D. Mannino,et al.  Worldwide epidemiology of chronic obstructive pulmonary disease. , 1999, Current opinion in pulmonary medicine.

[80]  R. Wilson Bacterial infection and chronic obstructive pulmonary disease. , 1999, European Respiratory Journal.

[81]  M. Moy,et al.  Health-related quality of life improves following pulmonary rehabilitation and lung volume reduction surgery. , 1999, Chest.

[82]  S. Campbell,et al.  For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. , 1999, Archives of internal medicine.

[83]  D. Postma,et al.  Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis , 1999, Thorax.

[84]  G. Criner,et al.  Improvements in lung function, exercise, and quality of life in hypercapnic COPD patients after lung volume reduction surgery. , 1999, Chest.

[85]  D. Brooks,et al.  The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. , 1998, Chest.

[86]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[87]  W. Stalman,et al.  Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. , 1998, Journal of epidemiology and community health.

[88]  J Zieliński,et al.  Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. , 1998, Chest.

[89]  J. Collet,et al.  Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. , 1997, American journal of respiratory and critical care medicine.

[90]  C. Pichard,et al.  Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. , 1997, American journal of respiratory and critical care medicine.

[91]  Alison E. Ries Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. American College of Chest Physicians. American Association of Cardiovascular and Pulmonary Rehabilitation. , 1997, Chest.

[92]  Darrell R. Schroeder,et al.  A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation , 1997 .

[93]  N. Banik,et al.  Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. , 1997, The European respiratory journal.

[94]  D. Mannino,et al.  Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. , 1997, American journal of respiratory and critical care medicine.

[95]  J. M. FitzGerald,et al.  Bronchodilator delivery in acute airflow obstruction. A meta-analysis. , 1997, Archives of internal medicine.

[96]  R. Zuwallack,et al.  Body composition and health-related quality of life in patients with obstructive airways disease. , 1997, The European respiratory journal.

[97]  J. Stoller Clinical features and natural history of severe α1-antitrypsin deficiency , 1997 .

[98]  T. Sensky,et al.  Psychosocial predictors of long-term success of in-patient pulmonary rehabilitation of patients with COPD. , 1997, The European respiratory journal.

[99]  T. Rochat,et al.  Management 1997 of chronic obstructive pulmonary disease. Working Group of the Swiss Society of Pneumology. , 1997, Schweizerische medizinische Wochenschrift.

[100]  R. Breiman,et al.  Prevention of pneumococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997 .

[101]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[102]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[103]  J. Heffner,et al.  Outcomes of advance directive education of pulmonary rehabilitation patients. , 1997, American journal of respiratory and critical care medicine.

[104]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.

[105]  J. Stoller Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture. , 1997, Chest.

[106]  D. Schroeder,et al.  A comparison of sustained-release bupropion and placebo for smoking cessation. , 1997, The New England journal of medicine.

[107]  [Guidelines for long-term home oxygen therapy in patients with chronic respiratory insufficiency. Swiss Society for Tuberculosis and Lung Diseases Control and Swiss Society of Pneumology]. , 1997, Schweizerische medizinische Wochenschrift.

[108]  J. P. Davis,et al.  Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[109]  Alan D. Lopez,et al.  Evidence-Based Health Policy--Lessons from the Global Burden of Disease Study , 1996, Science.

[110]  Gordon H Guyatt,et al.  Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease , 1996, The Lancet.

[111]  J. Crowley,et al.  Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. , 1996, American journal of respiratory and critical care medicine.

[112]  S. Rennard,et al.  Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. , 1996, Chest.

[113]  M. Decramer,et al.  Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[114]  E. Silverman,et al.  Risk factors for the development of chronic obstructive pulmonary disease. , 1996, The Medical clinics of North America.

[115]  D. Postma,et al.  Effects of long-term treatment with corticosteroids in COPD. , 1996, Chest.

[116]  M. Decramer,et al.  Peripheral muscle weakness contributes to exercise limitation in COPD. , 1996, American journal of respiratory and critical care medicine.

[117]  D. Maldonado,et al.  Woodsmoke exposure and risk for obstructive airways disease among women. , 1996, Chest.

[118]  J. Henningfield Nicotine medications for smoking cessation. , 1995, The New England journal of medicine.

[119]  J. Deslauriers,et al.  Indications for surgery and patient work-up for bullectomy. , 1995, Chest surgery clinics of North America.

[120]  E. Wouters,et al.  Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. , 1995, American journal of respiratory and critical care medicine.

[121]  B. Celli,et al.  Long-term oxygen therapy. , 1995, The New England journal of medicine.

[122]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[123]  M. Stewart Effective physician-patient communication and health outcomes: a review. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[124]  P. Barnes,et al.  Theophylline and phosphodiesterase inhibitors. , 1995, The European respiratory journal.

[125]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[126]  J. Cooper,et al.  Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. , 1995, The Journal of thoracic and cardiovascular surgery.

[127]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[128]  U. Ackermann-Liebrich,et al.  Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. , 1994, American journal of respiratory and critical care medicine.

[129]  A. Buist,et al.  In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial , 1994 .

[130]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[131]  P. Hawkey,et al.  Antibiotics in chronic obstructive pulmonary disease , 1994, BMJ.

[132]  B. Delclaux,et al.  Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. , 1994, The European respiratory journal.

[133]  D. Mant,et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.

[134]  O. Brändli,et al.  [High-caloric nutrition in chronic obstructive lung disease]. , 1994, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.

[135]  S. Rennard,et al.  Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Task Group on Mucoactive Drugs. , 1994, Chest.

[136]  A. Buist,et al.  The Lung Health Study. Baseline characteristics of randomized participants. , 1993, Chest.

[137]  B. Griffith,et al.  Lung transplantation: Report of the ATS workshop on lung transplantation , 1993 .

[138]  D. Postma,et al.  European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. , 1992, The European respiratory journal.

[139]  H Spiro,et al.  What is empathy and can it be taught? , 1992, Annals of internal medicine.

[140]  J. Fitting Nutritional support in chronic obstructive lung disease. , 1992, Thorax.

[141]  J. Samet,et al.  Epidemiologic approaches for assessing health risks from complex mixtures in indoor air. , 1991, Environmental health perspectives.

[142]  P. Howard,et al.  Oral almitrine in treatment of acute respiratory failure and cor pulmonale in patients with an exacerbation of chronic obstructive airways disease. , 1991, Thorax.

[143]  B. Burrows Epidemiologic evidence for different types of chronic airflow obstruction. , 1991, The American review of respiratory disease.

[144]  D. Clemmons,et al.  The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. , 1991, Chest.

[145]  G. Patterson,et al.  Comparison of outcomes of double and single lung transplantation for obstructive lung disease. The Toronto Lung Transplant Group. , 1991, The Journal of thoracic and cardiovascular surgery.

[146]  N. Pride,et al.  A "splitting" look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. , 1991, The European respiratory journal.

[147]  R. Dittus,et al.  Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. , 1991, Annals of internal medicine.

[148]  V. Kvetan,et al.  Growth hormone and pulmonary disease. Metabolic effects in patients receiving parenteral nutrition. , 1990, Archives of internal medicine.

[149]  T. Sensky,et al.  Patients' reactions to illness. , 1990, BMJ.

[150]  M. Becklake Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. , 1989, The American review of respiratory disease.

[151]  T. Thom International comparisons in COPD mortality. , 1989, The American review of respiratory disease.

[152]  O. Brändli,et al.  [Course and prognosis of chronic obstructive lung disease over 5 and 10 years]. , 1988, Schweizerische medizinische Wochenschrift.

[153]  D. Postma,et al.  Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? , 1988, The European respiratory journal.

[154]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[155]  N. Anthonisen,et al.  A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. , 1986, The New England journal of medicine.

[156]  D. Postma,et al.  Severe chronic airflow obstruction: can corticosteroids slow down progression? , 1985, European journal of respiratory diseases.

[157]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.

[158]  Cotes Je,et al.  LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMA Report of the Medical Research Council Working Party , 1981, The Lancet.

[159]  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. , 1980, Annals of internal medicine.

[160]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[161]  I. Grant Chronic Airflow Obstruction in Lung Disease , 1977 .

[162]  D. Smith,et al.  Five-year winter chemoprophylaxis for chronic bronchitis , 1969, British medical journal.